Alteogen's growth thesis lies in applying its platform technology to multiple drugs and translating commercialization performance into revenue. For the first half of 2026, preliminary consolidated revenue was announced at 140.5 billion KRW and operating profit at 73.5 billion KRW.
The expansion of partner product sales and the achievement of the first sales milestone demonstrate that the revenue path following technology transfer is taking shape. However, partner product sales differ from Alteogen's revenue, and milestones are distinct from royalties that repeat every period.
The maximum contract value for the Novartis agreement assumes the exercise of all options and the achievement of all milestones. KBR did not sum this up as confirmed revenue, but instead analyzed the value and uncertainty that change at each stage of contract, development, and commercialization.
We also examined research personnel, organizational knowledge accumulation, quality and information reliability, and environmental data. We distinguished between the potential of early-stage research and current commercialization performance, concluding that the long-term value of the platform depends on the extent to which repetitive, sales-linked revenue accumulates.
The 40-page KBR company analysis outlines strategy, organization, ESG, consolidated performance, and contract structures through 35 charts and analytical tables. The detailed report can be downloaded as a PDF for 49,000 KRW.
